Contribution of single-pill combinations in the management of hypertension: perspectives from China, Europe and the USA
| Autor: | Ulrike, Gottwald-Hostalek, Ningling, Sun |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Current Medical Research and Opinion. 39:331-340 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1080/03007995.2023.2165812 |
| Popis: | Uncontrolled hypertension is associated with an increased risk of adverse clinical vascular outcomes and death. Hypertension management guidelines from China and the USA recommend initiation of antihypertensive pharmacotherapy with a single drug for patients without severe hypertension at presentation. Current European hypertension guidelines take a different approach and recommend the use of combination therapy from the time of diagnosis of hypertension for most patients. This article reviews the burden of hypertension in these countries, and summarises the evidence base for the use of antihypertensive combination therapy contained within a single tablet (single-pill combinations, SPC). Typically, half or less of populations from China, Europe and the USA who were found to have hypertension were aware of their condition, less than half of those received treatment, and fewer still achieved adequate blood pressure (BP) control. The reasons for the unaddressed burden of hypertension are complex and multifactorial, with contributions from factors related to patients, healthcare providers and healthcare systems. The use of SPCs of antihypertensive therapies helps to optimise adherence with therapy and is likely to result in superior BP control. There is a strong evidence base to support current European guideline recommendations on the initiation of antihypertensive therapy with SPCs for the majority of people with hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|